2seventy bio, Inc. (TSVT) Research

2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.

Market snapshot

Symbol
TSVT
Price
$5.00
Day change
0.00%
Market cap
$266.1M
P/E ratio
-13.93x
52-week range
2.29-5.3
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$3.50

Peer companies

  • Catabasis Pharmaceuticals, Inc. (CATB)
  • CARGO Therapeutics, Inc. Common Stock (CRGX)
  • Inozyme Pharma, Inc. (INZY)
  • Lifecore Biomedical, Inc. (LFCR)
  • Merrimack Pharmaceuticals, Inc. (MACK)
  • scPharmaceuticals Inc. (SCPH)
  • Acelyrin, Inc. (SLRN)
  • Spectrum Pharmaceuticals, Inc. (SPPI)

Recent insider activity

  • Glickman Sarah JS — D-Return (12050 shares) on 2025-05-13
  • Glickman Sarah JS — U-Tender (15602 shares) on 2025-05-13
  • Glickman Sarah JS — D-Return (24100 shares) on 2025-05-13
  • Casdin Capital, LLC — D-Return (12050 shares) on 2025-05-13
  • Casdin Capital, LLC — D-Return (33400 shares) on 2025-05-13

Open 2seventy bio, Inc. (TSVT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.